Morich Frank has made a significant move by acquiring 15,000 shares of Perspective Therapeutics, Inc. This transaction, reported on November 16, 2026, is noteworthy as it reflects Frank's confidence in the pharmaceutical preparations sector.

The acquisition was executed on November 12, 2026, at a price of $0.9971 per share, which translates to approximately EUR 0.90 per share, as noted in the filing. The transaction showcases Frank's direct ownership of the shares, which now totals 15,000 shares following this acquisition.

Background

Morich Frank is a private entity involved in the life sciences sector. The company has been active in the market, with a series of recent filings indicating ongoing engagement with Perspective Therapeutics, Inc. Perspective Therapeutics, based in Seattle, WA, is classified under the SIC code for pharmaceutical preparations [2834]. This classification highlights its role in developing and providing pharmaceutical products.

What the Filing Says

The filing details the acquisition of shares, stating, "The purchase was made in euros at a price of EUR 0.90 per share." This indicates a strategic investment by Frank, who is a director at Perspective Therapeutics.

Impact

This acquisition may impact various stakeholders, particularly within the pharmaceutical industry. As a director, Frank's investment could influence the company's strategic direction and investor sentiment.

What's Next

The filing does not say what happens next.